title: The journey from discoveries in fundamental immunology to cancer immunotherapy.
abstract: Recent advances in cancer immunotherapy have directly built on 50 years of fundamental and technological advances that made checkpoint blockade and T cell engineering possible. In this review, we intend to show that research, not specifically designed to bring relief or cure to any particular disease, can, when creatively exploited, lead to spectacular results in the management of cancer. The discovery of thymus immune function, T cells, and immune surveillance bore the seeds for today's targeted immune interventions and chimeric antigen receptors.
authors: The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3050, Australia. Electronic address: miller@wehi.edu.au.
authors: Jacques F A P
authors: JF
authors: Miller
authors: The Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: m-sadelain@ski.mskcc.org.
authors: Michel
authors: M
authors: Sadelain
mesh_terms: D000486:Allergy and Immunology; D000818:Animals; D001402:B-Lymphocytes / Q000502:physiology; D019496:Cancer Vaccines / Q000627:therapeutic use; D006801:Humans; D007157:Immunologic Surveillance; D007167:Immunotherapy / Q000639:trends*; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D012106:Research; D013601:T-Lymphocytes / Q000502:physiology; D013950:Thymus Gland / Q000276:immunology
chemical_list: D019496:Cancer Vaccines